Literature DB >> 11464896

Generation of a humanised single chain Fv (Scfv) derived from the monoclonal Eric-1 recognising the human neural cell adhesion molecule.

H A Whittington1, J Hancock, J T Kemshead.   

Abstract

BACKGROUND: Murine monoclonal antibody (MoAb) ERIC-1 recognises an epitope on the neural cell adhesion molecule (NCAM) whose expression in paediatric and adult tissues is confined mainly to the brain, peripheral nerve, and adrenal medulla. Anti-NCAM antibodies have been used for the treatment and diagnosis of a number of tumours, including neuroblastoma. However, whole antibody exhibits poor penetration into solid tumour deposits and rapid systemic clearance upon repeated administration due to development of a human antimouse antibody (HAMA) response. PROCEDURE: To overcome these problems, recombinant DNA techniques have been used to humanise and assemble the ERIC-1 immunoglobulin variable heavy (VH) and light (VL) chains into a single chain Fv (scFv).
RESULTS: Three humanised scFv clones were identified which differ from the predicted humanised sequence by occasional amino acid changes, but these maintain the same specificity as the original ERIC-1 MoAb.
CONCLUSIONS: The humanised scFv may prove to be a useful reagents in the treatment and diagnosis of a variety of neuroectodermal tumours and can clearly form a suitable template for the generation of a fully humanised ERIC-1 MoAb.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464896     DOI: 10.1002/1096-911X(20010101)36:1<243::AID-MPO1060>3.0.CO;2-5

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  2 in total

1.  Primary targeting of recombinant Fv-immunotoxin hscFv(25)-mTNFalpha against hepatocellular carcinoma.

Authors:  Jing Zhang; Yan-Fang Liu; Shou-Jing Yang; Qing Qiao; Hong Cheng; Chuan-Shan Zhang; Fu-Cheng Ma; Hua-Zhang Guo
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

2.  T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches.

Authors:  A J Sheen; D J Sherlock; J Irlam; R E Hawkins; D E Gilham
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.